Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma - Outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: Results from the European group for blood and marrow transplantation

J. W. Sweetenham, R. Pearce, G. Taghipour, D. Biaise, C. Gisselbrecht, A. H. Goldstone

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Purpose: To investigate the results of treatment for adult patients with Burkitt's and Burkitt-like non-Hodgkin's lymphoma (NHL) undergoing high-dose therapy and autologous stem-cell transplantation (ASCT), and to determine prognostic factors for this group. Patients and Methods: A retrospective analysis of 117 adult patients reported to the lymphoma registry of the European Group for Blood and Marrow Transplantation (EBMT) between June 1984 and November 1994. Seventy of these patients received high-dose therapy and stem-cell transplantation in first complete remission (CR). Data on all patients were reviewed, and prognostic factors were determined by univariate and multivariate analysis. Results: The actuarial overall survival (OS) rate for the entire group was 53% at 3 years. The major factor predicting for outcome after transplantation was disease status: the 3-year actuarial OS rate was 72% for patients transplanted in first CR, compared with 37% for patients in chemosensitive relapse, and 7% for chemoresistant patients. For patients transplanted in first CR, disease bulk at the time of ASCT was the only factor predictive of progression-free survival (PFS) and OS. Conclusion: The results of high-dose therapy and ASCT for patients with relapsed disease, particularly chemosensitive relapse, are superior to those reported for conventional-dose salvage regimens. The results for patients transplanted in first CR require comparison with modern dose-intensive regimens.

Original languageEnglish (US)
Pages (from-to)2465-2472
Number of pages8
JournalJournal of Clinical Oncology
Volume14
Issue number9
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Blood Group Antigens
Non-Hodgkin's Lymphoma
Transplantation
Bone Marrow
Recurrence
Therapeutics
Survival Rate
Disease-Free Survival
Registries
Lymphoma
Multivariate Analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{e92e573894f8438b85c8be7ceab448c1,
title = "Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma - Outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: Results from the European group for blood and marrow transplantation",
abstract = "Purpose: To investigate the results of treatment for adult patients with Burkitt's and Burkitt-like non-Hodgkin's lymphoma (NHL) undergoing high-dose therapy and autologous stem-cell transplantation (ASCT), and to determine prognostic factors for this group. Patients and Methods: A retrospective analysis of 117 adult patients reported to the lymphoma registry of the European Group for Blood and Marrow Transplantation (EBMT) between June 1984 and November 1994. Seventy of these patients received high-dose therapy and stem-cell transplantation in first complete remission (CR). Data on all patients were reviewed, and prognostic factors were determined by univariate and multivariate analysis. Results: The actuarial overall survival (OS) rate for the entire group was 53{\%} at 3 years. The major factor predicting for outcome after transplantation was disease status: the 3-year actuarial OS rate was 72{\%} for patients transplanted in first CR, compared with 37{\%} for patients in chemosensitive relapse, and 7{\%} for chemoresistant patients. For patients transplanted in first CR, disease bulk at the time of ASCT was the only factor predictive of progression-free survival (PFS) and OS. Conclusion: The results of high-dose therapy and ASCT for patients with relapsed disease, particularly chemosensitive relapse, are superior to those reported for conventional-dose salvage regimens. The results for patients transplanted in first CR require comparison with modern dose-intensive regimens.",
author = "Sweetenham, {J. W.} and R. Pearce and G. Taghipour and D. Biaise and C. Gisselbrecht and Goldstone, {A. H.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1200/JCO.1996.14.9.2465",
language = "English (US)",
volume = "14",
pages = "2465--2472",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma - Outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse

T2 - Results from the European group for blood and marrow transplantation

AU - Sweetenham, J. W.

AU - Pearce, R.

AU - Taghipour, G.

AU - Biaise, D.

AU - Gisselbrecht, C.

AU - Goldstone, A. H.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Purpose: To investigate the results of treatment for adult patients with Burkitt's and Burkitt-like non-Hodgkin's lymphoma (NHL) undergoing high-dose therapy and autologous stem-cell transplantation (ASCT), and to determine prognostic factors for this group. Patients and Methods: A retrospective analysis of 117 adult patients reported to the lymphoma registry of the European Group for Blood and Marrow Transplantation (EBMT) between June 1984 and November 1994. Seventy of these patients received high-dose therapy and stem-cell transplantation in first complete remission (CR). Data on all patients were reviewed, and prognostic factors were determined by univariate and multivariate analysis. Results: The actuarial overall survival (OS) rate for the entire group was 53% at 3 years. The major factor predicting for outcome after transplantation was disease status: the 3-year actuarial OS rate was 72% for patients transplanted in first CR, compared with 37% for patients in chemosensitive relapse, and 7% for chemoresistant patients. For patients transplanted in first CR, disease bulk at the time of ASCT was the only factor predictive of progression-free survival (PFS) and OS. Conclusion: The results of high-dose therapy and ASCT for patients with relapsed disease, particularly chemosensitive relapse, are superior to those reported for conventional-dose salvage regimens. The results for patients transplanted in first CR require comparison with modern dose-intensive regimens.

AB - Purpose: To investigate the results of treatment for adult patients with Burkitt's and Burkitt-like non-Hodgkin's lymphoma (NHL) undergoing high-dose therapy and autologous stem-cell transplantation (ASCT), and to determine prognostic factors for this group. Patients and Methods: A retrospective analysis of 117 adult patients reported to the lymphoma registry of the European Group for Blood and Marrow Transplantation (EBMT) between June 1984 and November 1994. Seventy of these patients received high-dose therapy and stem-cell transplantation in first complete remission (CR). Data on all patients were reviewed, and prognostic factors were determined by univariate and multivariate analysis. Results: The actuarial overall survival (OS) rate for the entire group was 53% at 3 years. The major factor predicting for outcome after transplantation was disease status: the 3-year actuarial OS rate was 72% for patients transplanted in first CR, compared with 37% for patients in chemosensitive relapse, and 7% for chemoresistant patients. For patients transplanted in first CR, disease bulk at the time of ASCT was the only factor predictive of progression-free survival (PFS) and OS. Conclusion: The results of high-dose therapy and ASCT for patients with relapsed disease, particularly chemosensitive relapse, are superior to those reported for conventional-dose salvage regimens. The results for patients transplanted in first CR require comparison with modern dose-intensive regimens.

UR - http://www.scopus.com/inward/record.url?scp=0029761785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029761785&partnerID=8YFLogxK

U2 - 10.1200/JCO.1996.14.9.2465

DO - 10.1200/JCO.1996.14.9.2465

M3 - Article

C2 - 8823324

AN - SCOPUS:0029761785

VL - 14

SP - 2465

EP - 2472

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -